Etiology and clinical profile of patients with Cushing’s syndrome: A single center experience

Ariacherry C. Ammini, Nikhil Tandon, Nandita Gupta, Ashu Seith Bhalla1, Kandaswamy Devasenaspathy1, Guresh Kumar2, Jaiprakash P. Sahoo, Sachin Chittawar, Jim Philip, Manas P. Baruah, C. S. Dwarakanath, Sudhir Tripathi

Departments of Endocrinology and Metabolism, 1Radiology, and 2Biostatistics, AIIMS, New Delhi, India

ABSTRACT

Background: There is little published literature on the profile of patients with Cushing’s syndrome (CS) from India. The aim of this study was to compile data of CS patients treated at this hospital. Materials and Methods: Patients referred to the endocrine services of this hospital for diagnosis/treatment of CS from January 1985 to July 2012 were the subjects for this study. All patients had detailed medical history, physical examination and biochemical and hormonal assays (which changed with availability of tests and changing views). Assays for plasma adrenocorticotropic hormone (ACTH) (late 90s), salivary cortisol estimation, IJV sampling for ACTH and corticotrophin releasing hormone stimulation tests were added on later. Imaging included computed tomography (CT), magnetic resonance imaging (since the late 80’s) and 68Ga DOTA-TOC/FDG PET-CT (2008). Results: Three hundred sixty-four patients (250 females, 114 males, age 6 months to 65 years, mean 28 years + 12 years) were diagnosed to have CS during this period. Two hundred and ninety-three patients (80.5%) were ACTH dependent (CD 215, ectopic ACTH syndrome 22, occult ACTH source 56) while 71 (19.5%) were ACTH independent (adrenal carcinoma 36, adenoma 30, primary pigmented nodular adrenal disease 4, AIMAH 1). Pituitary macro adenoma was seen in 14% of the CD cases. The most common presenting complaints were hypertension and diabetes mellitus. A total of 63% patients complained of weight gain while 15% had lost weight. Myopathy, infections, skeletal fractures and psychiatric problems were the other common observations in our patients. Conclusion: The clinical spectrum was broad. CD was the most common cause for CS.

Key words: Adrenal adenoma, adrenal carcinoma, adrenocorticotropic hormone, adrenal cushing’s, cushing’s disease, cushing’s syndrome, ectopic adrenocorticotropic hormone syndrome

INTRODUCTION

Cushing’s syndrome (CS) is a complex endocrine disorder with potential for serious consequences if not adequately treated.[1] The incidence of CS varies in different studies from 0.7 to 2.4 per million populations per year.[2-3] A more recent study reported a prevalence of 79 per million and incidence of 1.8 per million per year for CS.[4] Nearly 80% of the cases of endogenous hypercortisolism are adrenocorticotropic hormone (ACTH) dependent, the ACTH source being pituitary in about 70-80% and ectopic in 10-15%.[5-9] The ACTH source may remain occult in few cases for many years in spite of extensive investigations. Primary adrenal disease (adrenal adenoma, adrenal carcinoma) accounts for about 15-20% of cases. CS is more common among certain high-risk groups, e.g., 2.5% among patients with type 2 diabetes mellitus with poor blood glucose control[10] and 0.5-1% among hypertensive patients.[11] CS patients experience significant clinical burden as a result of the physical illness, associated comorbidities like hypertension, diabetes mellitus, vulnerability to infections and associated psychopathology. Identification and management of this complex problem poses a greater challenge in a resource-poor country like India. Presented here is the profile of patients with CS attending this Tertiary Care Center since 1985.
Materials and Methods

Patients referred to the endocrine services of this hospital for evaluation/management of CS, from January 1985 to July 2012, are included in this study. All subjects had detailed clinical evaluation, including review of past medical records and medications. The protocol for evaluation of patients with suspected CS has changed considerably during the study period. In the 80s, patients with suspected CS had plasma cortisol measurement 6 h for 2 days to assess diurnal variation followed by low-dose (0.5 mg 6 h for 2 days) dexamethasone suppression test. Plasma cortisol urine 17 hydroxy steroids were measured. Cortisol was measured with fluorometric assays. Those confirmed to have hypocortisolism underwent computed tomography (CT) scan of the adrenal glands to exclude adrenal pathology. Those without an adrenal mass lesion underwent high-dose dexamethasone suppression test (HDDST) with 8 mg dexamethasone (2 mg 6 h for 2 days). Those who showed more than 50% suppression underwent CT (or magnetic resonance imaging (MRI) since the late 80’s, 0.5 Tesla) scan for pituitary gland. Those with non-suppressible cortisol on HDDST and those without a lesion on CT/MRI underwent further investigations to exclude an ectopic ACTH source. Those who had an adenoma (micro or macro) underwent pituitary surgery while those without a lesion underwent bilateral total adrenalectomy. MRI became available in this hospital during the late 80’s. Radioimmunoassay for ACTH and cortisol became freely available (on a commercial basis during the mid 80’s) in this hospital from the year 2000. Subsequently, late night salivary cortisol estimation, intravenous HDDST, 68Ga DOTA-TOC/ FDG PET-CT scan and bilateral internal jugular vein sampling for ACTH and corticotrophin releasing hormone (CRH) stimulation test have been added.

Now (after year 2000), two or more screening tests (ONDST, LDDST, late night salivary cortisol) are performed in addition to measurement of basal serum cortisol and plasma ACTH. Those with discordant results and those with low serum cortisol in the absence of history of steroid use are re-evaluated subsequently to exclude the possibility of cyclical hypocortisolism. ACTH dependent CS (plasma ACTH >10 pg/mL) patients underwent HDDST and MRI of pituitary (1.5 Tesla since 2007) with dynamic sequences with gadolinium. ACTH dependent CS patients with normal or inconclusive (lesion <5 mm) findings on MRI sella were further investigated to localize the ectopic source of ACTH with contrast-enhanced CT scan of the neck, chest, abdomen and pelvis. CRH stimulation test, bilateral internal jugular vein sampling for ACTH and 68Ga DOTA-TOC/ FDG PET-CT scan were performed as additional tests for the more recent cases.

Subjects with ACTH dependent CS where no pituitary or ectopic ACTH producing tumor could be identified were explained the pros and cons of pituitary exploration, bilateral adrenalectomy and medical therapy and given the option for choosing one of these modalities of treatment. They were subsequently followed-up for an evolving pituitary or ectopic ACTH source. Some patients with Cushing’s disease who were severely symptomatic (significant myopathy, multiple vertebral fractures, etc.) had bilateral adrenalectomy as a life-saving measure. These patients underwent pituitary surgery 6-12 months later. All treated patients were advised life-long follow-up.

At present, cortisol and ACTH are measured by the ECLISA technique. The measuring range for cortisol is 0.018-63.4 µg/dL. Estimation of plasma ACTH is performed using two monoclonal antibodies specific for ACTH (ACTH: 9-12 and ACTH: 36-39). The measuring range of ACTH assay is 1-2000 pg/mL with inter-assay and intra-assay CV <6%. MRI is performed on a 1.5T scanner (Siemens Avanto or Sonata, Erlangen, Germany). T1W spin echo sequences are obtained in the coronal and sagittal planes using thin slices (3 mm). Additional T2 fast spin echo sequences are performed in the coronal plane. Patients receive an intravenous gadolinium compound at a dose of 0.1 mmol/kg. Post-contrast T1W images are obtained in the coronal plane. Following contrast administration, both dynamic and routine images are performed. For dynamic imaging, fat-suppressed fast spin echo sequences are used.

There are no ethical issues regarding this study. Permission/waiver was obtained from the Institute Ethics Committee. SPSS version 15, Illinos Chicago, USA was used. Besides descriptive statistics, the two groups were compared by applying the Student t-test for continuous data. Qualitative data were compared by applying the Chi-square/Fisher’s test, $P<0.05$ was considered as significant.

Results

Three hundred and sixty-four patients were diagnosed to have CS (250 females and 114 males, age ranging from 6 months to 65 years [28 years + 12 years]) during these 27 years. Most of these patients were from Delhi and other parts of India. There were few patients from Afghanistan, Nepal and Bangladesh. Figure 1 shows the age and gender distribution of these patients. Nearly 70% of the patients were in the 10-40 year age group [Figure 1]. Female gender preponderance was seen after 10 years of age.
One hundred and twenty-one of these patients were diagnosed prior to 2000 (88 females and 33 males, age ranging from 6 months to 56 years [mean 27.08±12]) [Table 1]. Among them, 25 patients had ACTH independent hypercortisolism (13 adrenal carcinoma, 11 adenoma and one primary pigmented nodular adrenal disease [PPNAD]).

Five patients had ectopic ACTH syndrome (EAS) (four diagnosed during initial evaluation and one during follow-up). Among the other 91 patients, 61 had CD (12 pituitary macroadenoma, 42 microadenoma and seven normal pituitary on imaging [developed pituitary tumor during follow-up after bilateral adrenalectomy]); source of ACTH excess could not be established in 30 patients. Eleven of the twelve with pituitary macroadenoma had pituitary surgery as the initial therapy, seven of them required radiotherapy (external irradiation in five, Gamma knife in two) and six of these seven required bilateral adrenalectomy. One of these 12 patients underwent external irradiation for pituitary and bilateral total adrenalectomy at another center. One patient with microadenoma had a cerebellopontine angle tumor and another had breast carcinoma with secondaries; the other 40 patients underwent pituitary surgery. Bilateral total adrenalectomy was performed subsequently in 17 of these, four required additional pituitary surgery and/or radiotherapy. Nineteen of the thirty patients with normal pituitary had bilateral adrenalectomy, two died of septicemia with chest infection and nine were lost to follow-up.

One hundred and ninety-one patients were diagnosed to have CS (131 females and 60 males, age ranging from 2 years to 65 years [28.7±11.8]) between January 2000 and December 2009. Of these, 151 were ACTH dependent while 40 were ACTH independent. Among the ACTH dependent, 121 were due to CD (14 macroadenoma), 13 EAS (11 during initial evaluation and two on follow-up) and 17 occult ACTH source. Part of this is published.[17] Among the 40 patients with adrenal CS, 23 were adrenal carcinomas, 15 were adrenal adenoma, one was AIMAH and one was PPNAD.

Fifty-two patients (34 females and 18 males, age ranging from 12 years to 55 years [26.7±11.16 years]) were diagnosed to have CS between January 2010 and July 2012. Forty-six patients had ACTH dependent CS while six had ACTH independent hypercortisolism (four adrenal adenoma and two PPNAD). Among the 46 ACTH dependent CS patients, four had EAS (one thymic carcinoid and three bronchial carcinoid), 33 CD (four macroadenoma) and nine with occult ACTH source.

Altogether 293 (80.5%) were ACTH dependent CS, 71 (19.5%) were ACTH independent [Table 2]. Among 293 ACTH dependent cases, 215 (73%) were due to CD (30 [14%] pituitary macroadenoma), 22 (7.5%) were due to EAS and in 56 (19%), the ACTH source could not be identified (occult ACTH source). Figure 2 shows the etiology for CS in the different age groups. Number and size of macroadenomas were higher during the earlier period. Figure 3 shows the CT scan of a patient of CD diagnosed in 1998. Source of EAS was bronchial carcinoid (seven cases), thymic carcinoid (six cases), pancreatic neuroendocrine

| Table 1: Cushing’s syndrome patients evaluated during different periods |
|-----------------------------|----------------|----------------|----------------|--------------|
| Time period                | 1985-1999      | 2000-2009      | 2010-2012      | Total        |
| Number of patients         | 121            | 191            | 52             | 364          |
| Female/male                | 88/33          | 131/60         | 34/18          | 250/114      |
| Female %                   | 73%            | 69%            | 65%            | 69%          |
| ACTH dependent (%)          | 96 (79%)       | 151 (79%)      | 46 (88.5%)     | 293 (80.5%)  |
| CD (macroadenoma) (%)      | 61 (50%)       | 121 (63%)      | 33 (63%)       | 215 (59%)    |
| EAS (%)                    | 12 (20%)       | 14 (11.5%)     | 4 (12%)        | 30 (14%)     |
| UK (%)                     | 5 (5)          | 13 (11%)       | 4 (8%)         | 22 (7.5%)    |
| ACTH independent (%)       | 25 (21%)       | 40 (21%)       | 6 (11.5%)      | 71 (19.5%)   |
| Adrenal adenoma            | 11             | 15             | 4              | 30           |
| Adrenal carcinoma          | 13             | 23             | 36             |
| PPNAD                      | 1              | 1              | 4              |
| Macronodular adrenal hyperplasia | 1            | 1              |

ACTH: Adrenocorticotropic hormone, CD: Cushing’s disease, EAS: Ectopic adrenocorticotropic hormone syndrome, UK: Unknown, PPNAD: Primary pigmented nodular adrenal disease

Figure 1: Age and gender distribution of patients in different age groups

Figure 2: Etiology of Cushing’s syndrome in different age groups
tumor (four cases including one case of insulinoma), MEN 2 (medullary ca thyroid with ectopic ACTH secretion) (one case) and four cases of metastatic carcinoma (one each of squamous cell carcinoma, adenocarcinoma, small cell carcinoma and metastatic neuroendocrine tumor with unknown primary [tumorlets]). Figure 3 shows the etiology of EAS in the different age groups. Adrenal carcinoma (36), adrenal adenoma (30), PPNAD (4) and ACTH independent macronodular adrenal hyperplasia (1) accounted for the 71 ACTH independent CS cases. Figure 4 shows the age and gender distribution of patients with adrenal adenoma and adrenal carcinoma.

Hypertension and diabetes mellitus were the predominant presenting symptoms. Age and clinical profile of CD patients with pituitary macroadenoma was not significantly different from those with smaller pituitary lesions [Table 2]. Prevalence of hypertension, diabetes mellitus and obesity were 77%, 57% and 60%, respectively, among CD patients with pituitary macroadenoma, while it was 72%, 67% and 72% among those with pituitary microadenoma. Mean plasma ACTH was higher [Figure 5] and a lower number of patients showed >50% suppression with HDDST in the group with macroadenoma (not statistically significant).

Obesity was less common among EAS and adrenal carcinoma patients. Psychiatric manifestations were more common among EAS patients. Plasma ACTH was higher

Table 2: Profile of patients with Cushing’s syndrome

| Parameters                | Microadenoma (N=185) | Macroadenoma (N=30) | P value C1 versus C2 | Unknown (N=56) | Ectopic C3 (N=22) | P value (C1+C2) versus C4 | Adrenal adenoma (N=30) | Adrenal carcinoma (N=36) | P value C5 versus C6 |
|---------------------------|----------------------|---------------------|----------------------|----------------|------------------|--------------------------|-----------------------|---------------------------|-----------------------|
| Column                    | C1                   | C2                  |                      | C3             | C4 p             | C5                       | C6 p                  | N=359                     |
| F/M                      | 122±63               | 20:10               | NS                   | 42±14          | 12:10 NS         | 24±6                     | 28±9 NS               | 248:111                    |
| Age (mean±SD) years      | 27.6±11.5            | 26.9±8.3            | NS                   | 27.11          | 26.7±11.9 NS     | 34.7±16.3                | 29.36±15.8 NS         | 27.8±12                    |
| Duration                  | 3.2 years            | 3.10 years          | NS                   | 3.3 years      | 2 years NS       | 2.44 years               | 1.79 years            | NS                        |
| *Obesity (%)              | 134 (72.40)          | 18 (60)             | NS                   | 39 (62.5)      | 6 (27.7)         | <0.01                    | 18 (60)               | 14 (38.8)                 | 225 (62.6)             |
| HTN (%)                   | 133 (71.80)          | 23 (76.60)          | NS                   | 39 (69.6)      | 12 (54.4) NS     | 23 (76.60)               | 28 (77.7)            | 258 (71.8)                |
| DM (%)                    | 124 (67)             | 17 (56.60)          | NS                   | 37 (66)        | 13 (59) NS       | 15 (50)                  | 21 (58.30)            | 227 (63.2)                |
| Fractures (%)             | 47 (25.4)            | 6 (20)              | NS                   | 11 (19.6)      | 7 (31.8)         | <0.01                   | 4 (13.30)             | 5 (13.8) NS               | 80 (22.2)            |
| Psychiatric               | 57 (31)              | 5 (16.60)           | NS                   | 20 (35.7)      | 13 (59)         | 0.01                    | 6 (20)                | 8 (22.2) NS               | 109 (30.3)          |
| Striae (%)                | 113 (61)             | 19 (63.30)          | NS                   | 34 (60.7)      | 10 (45.4) NS     | 18 (60)                  | 12 (33.3)             | 206 (57.3)                |
| Hirsutism (%)             | 98 (80.3)            | 16 (80)             | NS                   | 35 (83.3)      | 11 (91.6) NS     | 16 (66.6)                | 26 (92.8)             | 202 (81.4)                |
| Menstrual irregularity (%)| 111 (91)             | 20 (100)            | <0.01                | 42 (100)       | 7 (58.3)         | <0.01                   | 12 (50)               | 22 (78.5)                 | 229 (92.3)            |
| Myopathy (%)              | 129 (70)             | 22 (73.3)           | NS                   | 35 (62.5)      | 15 (68) NS       | 20 (66.6)                | 27 (75)               | <0.01                    | 248 (69)             |
| Morning cortisol µg/dl    | 31.95±14.8           | 30.82±11.2          | NS                   | 33.4±13.8     | 34.6±22.7 NS     | 27.6±6.8                 | 34.8±11 NS            | NS                        |
| Evening cortisol µg/dl    | 25.6±10.3            | 30.2±9              | <0.01                | 20.37±10       | 36.4±24.8±0.01   | 25.13±8.6                | 30.9±9.6 NS            | NS                        |
| ACTH pg/ml                | 60.3±43              | 74.3±54             | NS                   | 80±32          | 103.8±87.3±0.01  | 5±14.5                  | 2.7±3.7 NS             | NS                        |
| Cortisol on LDDST µg/dl   | 22.7±12.3            | 22.9±12.4           | NS                   | 25.8±12       | 27.3±15.2 NS     | 24.6±6.6                 | 30.8±8.4±0.01         | NS                        |
| Cortisol on HDDST µg/dl   | 17.2±16.3            | 17.5±10.6           | NS                   | 18.3±15.8     | 28.3±14±0.01    | 29.6±5.6                 | 34±12.9 NS             | NS                        |
| HDDST>50% suppression     | 77/141               | 11/24               | NS                   | 4 (7%)         | 2 (9%)           | 0                       | 0                     | NS                        |

HDDST: High dose dexamethasone suppression test, LDDST: Low dose dexamethasone suppression test, NS: Not significant, ACTH: Adrenocorticotropic hormone, HTN: Hypertension, DM: Diabetes mellitus, F: Female, M: Male, SD: Standard deviation
among patients with EAS compared with patients with CD. Among CD patients, ACTH was higher among patients with pituitary macroadenoma. However, these were not statistically significant. Evening plasma cortisol was significantly higher among patients with EAS and adrenal carcinoma.

Ninety-one (26%) patients had skin infections, 15 patients had wound infections, nine patients had chest infection and four of these died of septicemia prior to any surgical intervention. Fifteen patients had tuberculosis, which included two adrenal tuberculosis and two intestinal tuberculosis with perforation and peritonitis. One of the patients with adrenal tuberculosis was misdiagnosed as adrenal adenoma and subjected to adrenalectomy. Histopathology revealed caseating granulomas with acid fast bacilli in addition to diffuse cortical hyperplasia. Five patients had herpes zoster.

Sixty-four patients had fractures, which included fracture hip in one patient, multiple rib and vertebral fractures. Two patients with vertebral fractures had paraparesis and one had paraplegia; all three were males with age ranging from 13 years to 26 years. Seven patients had avascular necrosis of bone, and the most common site was head of femur, others being head of humerus and carpel bones.

There were three patients with CD who developed pituitary apoplexy, two of them required surgery for hypercortisolism while one was asymptomatic without surgery.

Complaints were of cyclical nature in three patients (two F, one M), with length of cycles ranging from 2 weeks to 2 years. The first patient had normal cortisol levels during evaluation at our hospital, and MRI revealed pituitary microadenoma with hemorrhage. The second patient had several such episodes during a 6-year period, where she had weight gain followed by symptomatic hypocortisolism and weight loss of 16-20 kg. We observed one episode when her plasma cortisol was undetectable with low ACTH. She lost 25 kg (103-78 kg) during the next 1 year, which was followed by weight gain and increase in plasma cortisol and ACTH. The third patient was a 19-year-old male admitted with overt features of CS and no history of steroid use. Initial evaluation revealed low plasma cortisol, but repeat evaluation few weeks later revealed ACTH dependent hypercortisolism. Source of ACTH could not be identified in both these patients; they underwent bilateral adrenalectomy and are on follow-up.

Two women with CS (one with CD and another with unknown ACTH source) had venous thrombosis. The first patient had axillary vein thrombosis some years after cure of hypercortisolism while the other had a large thrombus extending from the inferior vena cava to the right atrium at the time of diagnosis of CS. X-ray of the chest of this patient showed miliary shadows that were mistaken for miliary tuberculosis. One young male patient had dilated cardiomyopathy, which recovered within 1 year of bilateral adrenalectomy.

One patient had carcinoma breast with secondaries in the liver at the time of diagnosis of CS and two women developed breast carcinoma several years after cure of hypercortisolism. Two of them had CD while the third had adrenal adenoma. Two patients with CD had acoustic neuromas.

**DISCUSSION**

Introduction of sensitive assays for ACTH and cortisol, higher resolution imaging techniques and better understanding of the etiology have changed the diagnostic and therapeutic strategy for patients with CS. Availability of ACTH assay has made it possible to distinguish between ACTH dependent and ACTH independent CS. However, identifying the ACTH source (pituitary versus ectopic) still continues to be a challenge. The present study included 364 CS patients evaluated during the last 27 years in the Endocrine services of this hospital. Seventy-one (19.5%) had primary adrenal disease while 293 (80.5%) were ACTH dependent. Unilateral adrenal disease (adrenal carcinoma 36, adenoma 30) accounted for most of the adrenal CS. There were four cases of PPNAD and one case of AIMAH. Among the cases of ACTH dependent CS, 215 (73.4%) were due to CD, 22 (7.5%) were due to EAS and 56 (19.1%) had occult ACTH source.
CD was the most common cause (59%) for CS in the present study, although it was less than in other published series. Table 3 compares the profile of CS patients in the present study with some large published series. Our patients were younger compared with CS patients in the Italian multicentric study and the Euro Cushing’s registry (mean age 28 years vs. 36 years and 43 years). Duration of symptoms prior to diagnosis was 3.2 years, which was longer compared with 29 months in the Italian multicenter study. Macroadenomas are reported in 4-10% of the cases with CD. In the present study, 30 (14%) of the 215 patients with CD had pituitary macroadenoma, proportion of patients with macroadenoma was higher among the earlier group (20% vs. 12%) compared with patients diagnosed more recently. There was a significant female preponderance in all etiological groups except EAS, like other published series. The number of patients diagnosed CS per year (8 vs. 19) and percentage of patients with EAS (5 vs. 17) was more after year 2000. The percentage of patients with pituitary macroadenoma among CD patients was higher (20% vs. 12%) during the earlier period. The size of the tumors was also bigger in the earlier group.

Common co-morbidities with CS are obesity, hypertension, diabetes mellitus, osteoporosis, infections and neurocognitive dysfunction. Hypertension and diabetes mellitus were the most common problems in the present study group. Prevalence of obesity was 65%, while 15% had weight loss. Those with weight loss were patients with a very long duration of symptoms, uncontrolled diabetes mellitus and infections like tuberculosis. About one-fifth of the CS patients had some infection. We did not observe significant difference in the clinical profile of patients with different etiology for cortisol excess except that obesity was less common among the EAS and adrenal carcinoma group and psychiatric problems were more common among EAS compared with the other groups.

Cyclicity/periodic hormonogenesis have been reported, although rarely, in patients with CS. Some of the hypotheses suggested to explain this phenomenon are episodic hemorrhage, synchronous growth and death of tumor cells, fluctuations in the hypothalamus–pituitary–adrenal axis, etc. Cyclicity has been defined as occurrence of three peaks and two troughs of hypercortisolemia. This is often difficult to establish as the intercycle period may be variable. There were three patients in this group with cyclical symptoms.

Skeletal fractures, avascular necrosis of bones, venous thrombosis, and cardiac dysfunction are well documented in patients with CS. One of our patients had extensive IVC thrombosis with miliary shadows in the lungs that was mistaken for milliary tuberculosis. One young man with CS had reversible dilated cardiomyopathy. Three patients had breast carcinoma (one at the time of diagnosis and two during follow-up) and two had acoustic neuroma. It is not possible to say whether there is a causal link or whether it is a coincidence, as these are not uncommon diseases.

Tubercular infection of adrenal glands causing adrenal insufficiency is well recognized. It has not been reported in patients with CS. Two CS patients in this study had unilateral adrenal tuberculosis.

The strength of this study is the large number of patients studied at a single center by the same investigators and the

### Table 3: Etiology of Cushing’s syndrome: Comparison with some published series

| Different studies     | Bertagna et al. | Newell-price et al. | Invitti et al. | Erem et al. | Shah et al. | Euro Cushing’s registry | Present study |
|-----------------------|-----------------|---------------------|---------------|-------------|-------------|-------------------------|--------------|
| Number of patients    | 809             | 150                 | 426           | 55          | 100         | 481                     | 364          |
| Year                  | 1970-1994       | 1979-1999           | 1983-2000     | 2004        | 2000-2010   | 1985-2012               |              |
| Pituitary (%)         | 550 (68)        | 110 (73)            | 288 (68)      | 39 (71)     | 69          | 317 (66)                | 215 (59)     |
| Ectopic (%)           | 58 (07)         | 12 (09)             | 25 (06)       | -           | 8           | 24 (5)                  | 22 (6)       |
| Unknown (%)           | -               | 08 (05)             | -             | 13          | -           | 13                      | 56 (15)      |
| Adrenal (%)           | Adenoma=111 (14)| 17 (11)             | 80 (18)       | 13 (24)     | Adenoma 2   | 130 (27)                | Adenoma 30 (8) |
|                       | Carcinoma 88 (11)|                    |               | Carcinoma 3 (5)| Carcinoma 8| 4 (1)                   | Carcinoma 36 (10)|
| PPNAD (%)             | 24 (06)         | 02 (0.2)            | 03 (02)       | 09 (02)     | -           | 4                       | 1            |
| AIMAH (%)             | -               | 02 (0.2)            | 03 (02)       | -           | 4           | 1                       | 3*           |
| Cyclical              | -               | -                   | -             | -           | -           | -                       | -            |

*All ACTH dependent Cushing’s syndrome, AIMAH: ACTH independantmacronodularadrenal hyperplasia, PPNAD: Primary pigmented nodular adrenal disease, ACTH: Adrenocorticotroic hormone
long-term follow-up. Some important diagnostic tools were not available during the major part of this study. That is one possible reason for the higher number of cases with occult ACTH source.

**CONCLUSION**

Cushing’s disease was the most common cause for CS; 14% patients with CD had pituitary macroadenoma. Etiology of ACTH/cortisol excess could not be established in 56 (15%) CS patients. Patients in this study were young, had long duration of illness, multiple metabolic abnormalities and coexisting infections.

**ACKNOWLEDGEMENT**

The authors gratefully acknowledge the contribution of the faculty of Departments of Neurosurgery, Surgery and Pediatric Surgery in the management of these patients.

**REFERENCES**

1. Lindholm J, Juel S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of cushing’s syndrome: A population-based study. J Clin Endocrinol Metab 2001;86:117-23.

2. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet 2006;367:1605-17.

3. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: An epidemiological approach. Clin Endocrinol (Oxf) 1994;40:479-84.

4. Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV, et al. Mortality and morbidity in Cushing’s syndrome in New Zealand. Clin Endocrinol (Oxf) 2011;75:436-42.

5. Bertagna, X., Raux-Demay, M.C., Guilhaume, B., Girard, F., Luton, J.P. (1995) Cushing’s disease. In: The Pituitary (ed. S. Melmed): Blackwell Science, Cambridge; 1995. p.478-545.

6. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the management of Cushing’s syndrome. J Endocrinol Invest 2003;26:65-72.

7. Conaglen JV, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA. Prospective evaluation of “Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: Preliminary results from a single centre study. Eur Radiol 2012;22:710-9.

8. Shah NS, Goel AH, Nagpal RD, Menon PS. Cushing’s disease: Management outcome in a tertiary care centre. J Assoc Physicians India 2006;54:919-22.

9. Anderson GH Jr, Blakeman N, Streenet DH. The effect of age on prevalence of secondary forms of hyperpertension in 4429 consecutively referred patients. J Hypertens 1994;12:609-15.

10. Tripathi S, Ammini AC, Bhatia R, Gupta R, Berry M, Sarkar C, et al. Cushing’s disease: Pituitary imaging. Australs Radiol 1994;38:183-6.

11. Jeyaraman K, Ammini AC, Nandita G, Dwivedi SN. Late-night salivary cortisol in normal subjects and in patients with Cushing’s syndrome. Postgrad Med J 2010;86:399-404.

12. Naswa N, Sharma P, Nazar AH, Agarwal KK, Kumar R, Ammini AC, et al. Prospective evaluation of “Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: Preliminary results from a single centre study. Eur Radiol 2012;22:710-9.

13. Sahoo JP, Seith A, Gupta N, Dwivedi S, Ammini AC. Internal jugular vein adrenocorticotrophic hormone estimation for diagnosis of adrenocorticotropic hormone-dependent Cushing’s syndrome: Ultrasound-guided direct jugular vein sample collection. Indian J Endocrinol Metab 2012;16:972-5.

14. Talbot JA, Kane JW, White A. Analytical and clinical aspects of adrenocorticotropic determination. Ann Clin Biochem 2003;40:453-71.

15. Ammini AC, Bhattacharya S, Sahoo JP, Philip J, Tandon N, Goswami R, et al. Cushing’s disease: results of treatment and factors affecting outcome. Hormones (Athens) 2011;10:222-9.

16. Woo YS, Isidori AM, Wat WZ, Kaltzas GA, Afshar F, Sabin I, et al. Clinical and biochemical characteristics of adrenocorticotropic-secreting macroadenomas. J Clin Endocrinol Metab 2008;90:4963-9.

17. Howlett TA, Drury PL, Perry L, Doniach I, Rees LH, Besser GM. Diagnosis and management of ACTH-dependent Cushing’s syndrome: Comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Ox) 1986;24:599-713.

18. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing’s syndrome due to ectopic corticotropin secretion: Twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab 2005;90:4955-62.

19. Isidori AM, Kaltzas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, et al. The ectopic adrenocorticotropin syndrome: Clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 2006;91:371-7.

20. Kaltzas GA, Giannulis MG, Newell-Price JD, Dacie JE, Thakkar C, Afshar F, et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing’s disease and the occult ectopic adrenocortotropic syndrome. J Clin Endocrinol Metab 1999;84:487-92.

21. Meiniard JR, Wolffentutel BH, Dullart RP. Cyclic Cushing’s syndrome: A clinical challenge. Eur J Endocrinol 2007;157:245-54.

22. Alexandraki KI, Kaltzas GA, Isidori AM, Akker SA, Drake WM, Chew SL, et al. The prevalence and characteristic features of cyclicity and variability in Cushing’s disease. Eur J Endocrinol 2009;160:1011-8.

23. Sniijwer DJ, van Zaane B, Cannegieter SC, Meinardi JR, Wolffenbuttel BH, J.P. (1995) Cushing’s disease. In: The Pituitary (ed. S. Melmed): Blackwell Science, Cambridge; 1995. p.478-545.

24. Afshar F, Chino I, Stuijver DJ, van Zaane B, Feelders RA, Debeij J, Cannegieter SC. Mortality and morbidity in Cushing’s syndrome. J Clin Endocrinol Metab 2011;96:3525-32.

25. Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA. Cardiac dysfunction is reversed upon successful treatment of Cushing’s syndrome. J Endocrinol Invest 2007;20:101-8.

26. Ammini AC, Tandon N, Gupta N, Bhaila AS, Devanesanapathy K, Kumar G, et al. Etiology and clinical profile of patients with Cushing’s syndrome: A single center experience. Indian J Endocr Metab 2014;18:99-105.

**Source of Support:** Nil. **Conflict of Interest:** None declared.